A detailed history of Bank Of America Corp transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 36,811 shares of DSGN stock, worth $230,068. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,811
Previous 32,284 14.02%
Holding current value
$230,068
Previous $108,000 83.33%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.19 - $5.88 $14,441 - $26,618
4,527 Added 14.02%
36,811 $198,000
Q2 2024

Aug 14, 2024

SELL
$3.23 - $4.77 $42,354 - $62,549
-13,113 Reduced 28.89%
32,284 $108,000
Q1 2024

May 15, 2024

SELL
$2.27 - $4.03 $92,936 - $164,992
-40,941 Reduced 47.42%
45,397 $182,000
Q4 2023

Feb 14, 2024

BUY
$1.99 - $2.76 $16,835 - $23,349
8,460 Added 10.86%
86,338 $228,000
Q2 2023

Aug 14, 2023

BUY
$4.99 - $7.64 $107,958 - $165,291
21,635 Added 38.47%
77,878 $490,000
Q1 2023

May 12, 2023

SELL
$5.5 - $9.77 $1.32 Million - $2.34 Million
-239,617 Reduced 80.99%
56,243 $324,000
Q4 2022

Feb 10, 2023

BUY
$7.86 - $17.2 $1.8 Million - $3.94 Million
228,971 Added 342.31%
295,860 $3.04 Million
Q3 2022

Nov 14, 2022

BUY
$14.09 - $25.57 $548,298 - $995,030
38,914 Added 139.1%
66,889 $1.12 Million
Q2 2022

Aug 12, 2022

SELL
$9.91 - $17.33 $289,609 - $506,451
-29,224 Reduced 51.09%
27,975 $391,000
Q1 2022

May 16, 2022

BUY
$11.17 - $20.89 $25,266 - $47,253
2,262 Added 4.12%
57,199 $924,000
Q4 2021

Feb 08, 2022

BUY
$13.64 - $21.41 $317,907 - $499,002
23,307 Added 73.69%
54,937 $1.18 Million
Q3 2021

Nov 15, 2021

BUY
$13.99 - $20.03 $352,939 - $505,316
25,228 Added 394.06%
31,630 $465,000
Q2 2021

Sep 13, 2021

BUY
$19.02 - $29.78 $121,766 - $190,651
6,402 New
6,402 $127,000

Others Institutions Holding DSGN

About Design Therapeutics, Inc.


  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $349M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.